Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 126.92 -0.61 (-0.48%)
price chart
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Johnson & Johnson Announces Completion of Synthes Acquisition
NEW BRUNSWICK, N.J., June 14, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock.
Johnson & Johnson's Synthes Deal Revives Foreign Tax Debate  Forbes
Johnson & Johnson completes $20B takeover of Synthes
Johnson & Johnson Should Split Up Says Goldman
Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Johnson & Johnson Unit to Halt Urinary Implants
Johnson & Johnson's Ethicon division will stop selling four types of mesh implants used to treat urinary incontinence, the company announced in a letter to judges overseeing two large groups of lawsuits filed by women who claim the devices caused ...
Johnson & Johnson to stop selling surgical mesh  Fox News
Transvaginal Mesh Lawyer Adam Slater of Mazie Slater Katz & Freeman, LLC ...  PR Web (press release)
BREAKING: Johnson & Johnson Drops ALEC
Pharmaceutical giant Johnson and Johnson announced today that they are dropping their membership from the American Legislative Exchange Council (ALEC).
Johnson & Johnson kept selling vaginal mesh implants after warnings
Johnson & Johnson continued to sell a vaginal mesh implant for nine months after U.S. regulators told the company to stop marketing the device, according to court records.
Johnson & Johnson: A Lucrative Buy On Synthes Acquisition
Johnson & Johnson (NYSE:JNJ) just announced that it has completed the acquisition of Synthes. The company is the world's largest maker of implants to mend bone fractures and also producer of surgical power tools and advanced biomaterials.
Polaris, J&J Idea to Solve Drug R&D Crisis: Work Together Early
One of those experiments is gradually starting to take shape between Polaris Venture Partners and Johnson & Johnson. Polaris, as readers in the Boston area know well, is one of the big fish in the life sciences innovation community, with $3 billion of ...
J&J, Polaris pact follows series of pharma/VC combos  FierceBiotech
Baby Soaps and Shampoos Trigger Positive Marijuana Tests
Commonly used baby soaps and shampoos, including products from Johnson & Johnson, Aveeno and CVS, can trigger a positive result on newborns' marijuana screening tests, according to a recent study.
Chemicals in Baby Shampoos Lead to False Marijuana Positives  ABC News
Baby Soap Triggers False-Positive Test Results For Marijuana  RedOrbit
Where's Johnson & Johnson's Growth? Look Internationally
Looking over some of the sales information on Johnson & Johnson (NYSE:JNJ), it's pretty clear that the company is relying more and more on international sales to drive overall revenues.